The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Amgen
Preclinical evaluation of XPO1 inhibition in Wilms tumors.
 
Michael Vincent Ortiz
No Relationships to Disclose
 
Armaan Siddiquee
No Relationships to Disclose
 
Daoqi You
No Relationships to Disclose
 
Prabhjot Singh Mundi
No Relationships to Disclose
 
Lianna Marks
No Relationships to Disclose
 
Kristina Guillan
No Relationships to Disclose
 
Daniel Diolaiti
No Relationships to Disclose
 
Mahalaxmi Aburi
No Relationships to Disclose
 
Andrea Califano
Stock and Other Ownership Interests - DarwinHealth; regeneron; Teva
Honoraria - Shanghai Cell Therapy Group; Xiamen Enchang Group
Consulting or Advisory Role - Abbvie; DarwinHealth
Patents, Royalties, Other Intellectual Property - The technology developed by my lab, including ARACNe, VIPER, OncoTreat/OncoTarget, MINDy, and DEMAND were licensed exclusively to DarwinHealth, Inc. Columbia receives royalties from these licenses and both my lab and I share a portion of these roylaties
Travel, Accommodations, Expenses - Abbvie; DarwinHealth
 
Filemon S. Dela Cruz
No Relationships to Disclose
 
Andrew Kung
Stock and Other Ownership Interests - Imago Pharma; Isabl Technologies
Consulting or Advisory Role - DarwinHealth; Emendo; Imago Pharma; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Royalty from licensing agreements with MI Bioresearch